Antidepressant-Associated Treatment Emergent Mania

Abstract Background The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression. Methods Studies that examined the association between clinical and genetic risk factors, specifically monoaminergic transporter genetic variation, and TEM were identified. A meta-analysis was performed using the odds ratio to estimate the effect size under the Der-Simonian and Laird model. Results Seven studies, referencing the SLC6A4 5-HTTLPR polymorphism and TEM (total N = 1578; TEM+ =594, TEM− = 984), of 142 identified articles were included. The time duration between the start of the AD to emergence of TEM ranged from 4 to 12 weeks. There was a nominally significant association between the s allele of the 5-HTTLPR polymorphism and TEM (odds ratio, 1.434; 95% confidence interval, 1.001–2.055; P = 0.0493; I2 = 52%). No studies have investigated norepinephrine or dopamine transporters. Conclusion Although the serotonin transporter genetic variation is commercially available in pharmacogenomic decision support tools, greater efforts, more broadly, should focus on complete genome-wide approaches to determine genetic variants that may contribute to TEM. Moreover, these data are exemplary to the merits of developing risk stratification models, which include both clinical and biological risk factors, to guide when not to use ADs in bipolar disorder. Future studies will need to validate new risk models that best inform the development of personalized medicine best practices treating bipolar depression.

[1]  M. Frye,et al.  Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania , 2022, Molecular Psychiatry.

[2]  F. Markowetz,et al.  Multi-omic machine learning predictor of breast cancer therapy response , 2021, Nature.

[3]  Jeffrey H. Chuang,et al.  Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer , 2021, Modern Pathology.

[4]  A. Carvalho,et al.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment , 2021, Frontiers in Psychiatry.

[5]  P. Gibbs,et al.  MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer , 2020, EBioMedicine.

[6]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[7]  A. Nierenberg,et al.  20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. , 2020, The American journal of psychiatry.

[8]  J. Kennedy,et al.  Antidepressant-Associated Mania in Bipolar Disorder: A Review and Meta-analysis of Potential Clinical and Genetic Risk Factors. , 2020, Journal of clinical psychopharmacology.

[9]  M. Alda,et al.  Prediction of lithium response using clinical data , 2019, Acta psychiatrica Scandinavica.

[10]  G. Malhi,et al.  The delay in response to antidepressant therapy: A window of opportunity? , 2020, The Australian and New Zealand journal of psychiatry.

[11]  Gerta Rücker,et al.  How to perform a meta-analysis with R: a practical tutorial , 2019, Evidence-Based Mental Health.

[12]  A. Rush,et al.  Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. , 2019, Journal of affective disorders.

[13]  J. Mann,et al.  Depression , 2018, The Lancet.

[14]  Anne-Christin Hauschild,et al.  GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. , 2018, Journal of psychiatric research.

[15]  A. Andreazza,et al.  Bipolar Disorder as a Mitochondrial Disease , 2017, Biological Psychiatry.

[16]  Tadafumi Kato,et al.  Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond , 2017, Schizophrenia Research.

[17]  Etienne Sibille,et al.  Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. , 2017, The American journal of psychiatry.

[18]  A. Carvalho,et al.  Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications , 2016, Neuroscience & Biobehavioral Reviews.

[19]  A. Gaedigk,et al.  Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder , 2016, Medicine.

[20]  P. V. von Hippel,et al.  The heterogeneity statistic I2 can be biased in small meta-analyses , 2015, BMC Medical Research Methodology.

[21]  Paul T. von Hippel,et al.  The heterogeneity statistic I 2 can be biased in small meta-analyses , 2015 .

[22]  Brian A Palmer,et al.  Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. , 2015, The Journal of clinical psychiatry.

[23]  M. Thase,et al.  The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. , 2014, The American journal of psychiatry.

[24]  J. Calabrese,et al.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. , 2013, The American journal of psychiatry.

[25]  R. Perlis A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder , 2013, Biological Psychiatry.

[26]  M. T. Ryan,et al.  Supplemental Digital Content , 2013 .

[27]  Rebecca M Turner,et al.  Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis , 2011, BMC medical research methodology.

[28]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[29]  A. Serretti,et al.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.

[30]  Jun-Feng Wang,et al.  Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. , 2010, Archives of general psychiatry.

[31]  A. Young,et al.  A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). , 2010, The Journal of clinical psychiatry.

[32]  Ji-Hyun Kim,et al.  Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap , 2009, Comput. Stat. Data Anal..

[33]  J. Calabrese,et al.  The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. , 2009, Bipolar disorders.

[34]  Thomas G Schulze,et al.  Genetic predictors of response to antidepressants in the GENDEP project , 2009, The Pharmacogenomics Journal.

[35]  H. Corrêa,et al.  The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. , 2009, Journal of affective disorders.

[36]  A. Nierenberg,et al.  Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. , 2008, Journal of affective disorders.

[37]  R. Kravitz,et al.  Depression , 2007, Annals of Internal Medicine.

[38]  K. Chang,et al.  A Pilot Study of Antidepressant-Induced Mania in Pediatric Bipolar Disorder: Characteristics, Risk Factors, and the Serotonin Transporter Gene , 2006, Biological Psychiatry.

[39]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[40]  S. Easteal,et al.  Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  A. Altamura,et al.  Clinical variables related to antidepressant-induced mania in bipolar disorder. , 2006, Journal of affective disorders.

[42]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[43]  V. Pérez,et al.  Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder , 2006, Psychiatric genetics.

[44]  M. Leboyer,et al.  Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism , 2005, The Pharmacogenomics Journal.

[45]  C. Cusin,et al.  Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder , 2004, Psychopharmacology.

[46]  E. Mundo,et al.  The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. , 2001, Archives of general psychiatry.

[47]  Ron Kohavi,et al.  A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.

[48]  L. Altshuler,et al.  Antidepressant-induced mania and cycle acceleration: a controversy revisited. , 1995, The American journal of psychiatry.

[49]  M. Frye,et al.  Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. , 2012, Journal of affective disorders.

[50]  A. Andreazza,et al.  Is bipolar disorder a mitochondrial disease? , 2007, Journal of psychiatry & neuroscience : JPN.

[51]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[52]  Ali Reza Torabi,et al.  Author ' s , 2004 .